Inhibace

Cilazapril, the active ingredient in Inhibace, is an angiotensin‑converting enzyme (ACE) inhibitor presented as an oral tablet for oral use. It is prescribed to lower high blood pressure and to manage heart failure in adult patients.

GNH USA supplies Inhibace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from comprehensive regulatory support and consistent product availability across markets worldwide.

Cilazapril acts on the renin‑angiotensin system and is used in several cardiovascular conditions.

Hypertension: lowers systolic and diastolic blood pressure to achieve target levels. Heart failure: improves cardiac output and reduces symptoms such as dyspnea and edema. Post‑myocardial infarction: helps prevent adverse ventricular remodeling and subsequent cardiovascular events.

Cilazapril may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Persistent dry cough - Dizziness or light‑headedness, especially after standing - Headache - Fatigue or general weakness - Mild hypotension - Altered taste perception

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or airway - Severe neutropenia or agranulocytosis - Acute liver injury with jaundice - Significant renal impairment or rise in serum creatinine - Anaphylactoid reactions with rash and bronchospasm

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte balance: monitor potassium levels, especially if combined with potassium‑sparing agents. - History of angioedema: avoid use in patients with prior ACE‑inhibitor–related swelling. - Pregnancy and lactation: use only if clearly indicated after risk‑benefit analysis. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Cilazapril can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction and hyperkalemia. - Lithium: concomitant use may raise lithium levels, leading to toxicity. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function. - Diuretics (loop or thiazide): may enhance hypotensive response; monitor blood pressure and electrolytes.